[1]王可欣,马心迪,刘 剑,等.肝型脂肪酸结合蛋白与相关疾病的研究[J].医学信息,2020,33(10):23-26.[doi:10.3969/j.issn.1006-1959.2020.10.007]
 WANG Ke-xin,MA Xin-di,LIU Jian,et al.Study on Liver-type Fatty Acid Binding Proteins and Related Diseases[J].Medical Information,2020,33(10):23-26.[doi:10.3969/j.issn.1006-1959.2020.10.007]
点击复制

肝型脂肪酸结合蛋白与相关疾病的研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年10期
页码:
23-26
栏目:
综述
出版日期:
2020-05-15

文章信息/Info

Title:
Study on Liver-type Fatty Acid Binding Proteins and Related Diseases
文章编号:
1006-1959(2020)10-0023-04
作者:
王可欣马心迪刘 剑
(1.河北医科大学第二医院药学部,河北 石家庄 050000;2.河北医科大学第四医院,河北 石家庄 050011;3.石家庄市第三医院药剂科,河北 石家庄 050000;4.河北医科大学药理学教研室,河北 石家庄 050017)
Author(s):
WANG Ke-xinMA Xin-diLIU Jianet al
(1.Department of Pharmacy,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,Hebei,China;2.The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,Hebei,China;3.Department of Pharmacy,Shijiazhuang Third Hospital,Shijiazhuang 050000,Hebei,China;4.Department of Pharmacology,Hebei Medical University,Shijiazhuang 050017,Hebei,China)
关键词:
肝型脂肪酸结合蛋白肝损伤恶性肿瘤肾脏疾病糖尿病
Keywords:
Liver-type fatty acid binding proteinsLiver injuryMalignant tumorKidney diseaseDiabetes
分类号:
Q591.5
DOI:
10.3969/j.issn.1006-1959.2020.10.007
文献标志码:
A
摘要:
肝型脂肪酸结合蛋白(FABP1)属于脂肪酸结合蛋白(FABPs)家族的成员之一,是肝脏中唯一表达可结合长链脂肪酸的胞质蛋白,在脂肪酸的吸收、转运等过程中发挥重要作用。近年研究表明FABP1表达异常与脂代谢异常相关疾病密切相关,同时其表达异常与肾脏疾病、药物性肝损伤及恶性肿瘤等亦有一定的关系。本文主要对FABP1的结构、功能及其和肝脏疾病、肾脏疾病、糖尿病及肿瘤的关系进行综述,旨在为临床相关疾病的防治提供新的治疗靶点和治疗策略。
Abstract:
Liver-type fatty acid binding protein (FABP1) is a member of the family of fatty acid binding proteins (FABPs), it is the only cytoplasmic protein in the liver that can bind long-chain fatty acids and plays an important role in fatty acid absorption and transport. Recent studies have shown that abnormal expression of FABP1 is closely related to diseases related to abnormal lipid metabolism, and that abnormal expression is also related to kidney disease, drug-induced liver injury and malignant tumors. This article mainly reviews the structure and function of FABP1 and its relationship with liver disease, kidney disease, diabetes and tumor, and aims to provide new therapeutic targets and treatment strategies for the prevention and treatment of clinically related diseases.

参考文献/References:

[1]王慧,郑立,文逸凡,等.动物FABP基因家族研究进展及育种应用探讨[J].基因组学与应用生物学,2018,37(12):5275-5280.[2]林茂上.卵形鲳鯵仔、稚鱼脂肪酸结合蛋白克隆与表达的研究[D].大连海洋大学,2018.[3]盘道兴,王振,杨茂林,等.江口萝卜猪FABPs主要家族基因SNPs筛选及生物信息学分析[J].基因组学与应用生物学,2015,34(1):47-52.[4]黄荣东.FABP1基因启动子多态性与血脂的关联及功能研究[D].福建医科大学,2016.[5]吴云丽.乙型肝炎病毒X蛋白(HBx)对人FABP1和NQO1基因调控及机制研究[D].福建医科大学,2012.[6]Schroeder F,McIntosh AL,Martin GG,et al.Fatty Acid Binding Protein-1(FABP1)and the Human FABP1 T94A Variant:Roles in the Endocannabinoid System and Dyslipidemias[J].Lipids,2016,51(6):655-676.[7]Galassi VV,Villarreal MA,Montich GG.Relevance of the protein macrodipole in the membrane-binding process.Interactions of fatty-acid binding proteins with cationic lipid membranes[J].PLoS One,2018,13(3):e0194154.[8]姜华,高建鹏,胡阳,等.肝性脂肪酸结合蛋白基因单核苷酸多态性表达与NAFLD的相关性[J].实用医学杂志,2020(1):84-88.[9]Martin GG,Seeger DR,McIntosh AL,et al.Sterol Carrier Protein-2/Sterol Carrier Protein-x/Fatty Acid Binding Protein-1 Ablation Impacts Response of Brain Endocannabinoid to High-Fat Diet[J].Lipids,2019,54(10):583-601.[10]Elmes MW,Prentis LE,McGoldrick LL,et al.FABP1 controls hepatic transport and biotransformation of 9-THC[J].Scientific Reports,2019,9(1):7588.[11]Li WW,Huang D,Shen PC,et al.Effects of Gubentongluo Formula on Oxidative Stress Reflected by Expressions of PPARα and FABP1 in Mice with IgA Nephropathy[J].Journal of Sichuan University(Medical Science Edition),2017,48(2):210-215.[12]Church RJ,Kullak-Ublick GA,Aubrecht J,et al.Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury:An international collaborative effort[J].Hepatology,2019,69(2):760-773.[13]Meunier L,Larrey D.Drug-Induced Liver Injury:Biomarkers,Requirements,Candidates,and Validation[J].Front Pharmacol,2019(10):1482. [14]Mikus M,Drobin K,Gry M,et al.Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury[J].Liver Int,2017,37(1):132-140.[15]Belcher JM,Garcia-Tsao G,Sanyal AJ,et al.Urinary biomarkers and progression of AKI in patients with cirrhosis[J].Clin J Am Soc Nephrol,2014,9(11):1857-1867.[16]Mukai T,Egawa M,Takeuchi T,et al.Silencing of FABP1 ameliorates hepatic steatosis,inflammation,and oxidative stress in mice with nonalcoholic fatty liver disease[J].FEBS Open Bio,2017,7(7):1009-1016.[17]Pi H,Liu M,Xi Y,et al.Long-term exercise prevents hepatic steatosis:a novel role of FABP1 in regulation of autophagy-lysosomal machinery[J].FASEB J,2019,33(11):11870-11883.[18]张英.CBR1和FABP1在联苯双酯抗大鼠肝纤维化中的作用[D].河北医科大学,2015.[19]钟承千.脂肪型脂肪酸结合蛋白在肝细胞癌发生发展中的功能和机制研究[D].福建医科大学,2017.[20]Ku CY,Liu YH,Lin HY,et al.Liver fatty acid-binding protein(FABP1)promotes cellular angiogenesis and migration in hepatocellular carcinoma[J].Oncotarget,2016,7(14):18229-18246.[21]Sharaf RN,Butte AJ,Montgomery KD,et al.Computational prediction and experimental validation associating FABP-1 and pancreatic adenocarcinoma with diabetes[J].BMC Gastroenterology,2011(11):5.[22]Dharmarajan S,Newberry EP,Montenegro G,et al.Liver fatty acid-binding protein(L-Fabp)modifies intestinal fatty acid composition and adenoma formation in ApcMin/+ mice[J].Cancer Prev Res(Phila),2013,6(10):1026-1037.[23]Jiang Z,Shen H,Tang B,et al.Quantitative proteomic analysis reveals that proteins required for fatty acid metabolism may serve as diagnostic markers for gastric cancer[J].Clin Chim Acta,2017(464):148-154.[24]Wood SM,Gill AJ,Brodsky AS,et al.Fatty acid-binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon γ pathway[J].Mod Pathol,2017,30(1):123-133.[25]Parr SK,Clark AJ,Bian A,et al.Urinary L-FABP predicts poor outcomes in critically ill patients with early acute kidney injury[J].Kidney Int,2015,87(3):640-648.[26]Lewandowska L,Malyszko J,Joanna Matuszkiewicz-Rowińska J.Urinary and Serum Biomarkers for Prediction of Acute Kidney Injury in Patients Undergoing Liver Transplantation[J].Ann Transplant,2019(24):291-297.[27]祁洁,王钊华,董自杰,等.尿KIM-1、L-FABP、NGAL检测对早期AKI患儿的诊断价值探讨[J].临床和实验医学杂志,2019,18(22):2438-2441. [28]Katayama M,Miyazaki T,Ohata K,et al.Temporal changes in urinary excretion of liver-type fatty acid binding protein(L-FABP)in acute kidney injury model of domestic cats:a preliminary study[J].J Vet Med Sci,2019,81(12):1868-1872.[29]Watanabe S,Ichikawa D,Sugaya T,et al.Urinary Level of Liver-Type Fatty Acid Binding Protein Reflects the Degree of Tubulointerstitial Damage in Polycystic Kidney Disease[J].Kidney Blood Press Res,2018,43(6):1716-1729.[30]Plesiński K,Adamczyk P,Swietochowska E,et al.Evaluation of liver-type fatty acid binding protein(L-FABP)and interleukin 6 in children with renal cysts[J].Adv Clin Exp Med,2019,28(12):1675-1682.[31]Panduru NM,Forsblom C,Saraheimo M,et al.Urinary liver-type fatty acid binding protein is an independent predictor of stroke and mortality in individuals with type 1 diabetes[J].Diabetologia,2017,60(9):1782-1790.[32]Suh JS,Kim SH,Cho KS,et al.Urinary markers in the early stage of nephropathy in patients with childhood-onset type 1 diabetes[J].Pediatr Nephrol,2016,31(4):623-631.[33]Yang X,Zhang B,Lu X,et al.Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease:post-hoc findings from a multi-center,randomized,double-blind,placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease[J].BMC Complementary and Alternative Medicine,2016(16):246.

相似文献/References:

[1]李新刚.抗结核药物治疗所致肝损伤患者的危险因素及其治疗转归观察[J].医学信息,2019,32(03):155.[doi:10.3969/j.issn.1006-1959.2019.03.051]
 LI Xin-gang.Risk Factors and Treatment Outcomes of Patients with Liver Injury Caused by Anti-tuberculosis Drugs[J].Medical Information,2019,32(10):155.[doi:10.3969/j.issn.1006-1959.2019.03.051]
[2]付晓春,沈小莉,李红群,等.雷公藤多苷促进斑马鱼肝脏损伤和氧化应激的实验研究[J].医学信息,2019,32(05):79.[doi:10.3969/j.issn.1006-1959.2019.05.024]
 FU Xiao-chun,SHEN Xiao-li,LI Hong-qun,et al.Experimental Study on the Effects of Tripterygium Glycosides on Liver Damage and Oxidative Stress in Zebrafish[J].Medical Information,2019,32(10):79.[doi:10.3969/j.issn.1006-1959.2019.05.024]
[3]蒋红梅.丙基硫氧嘧啶与甲巯咪唑治疗妊娠合并甲状腺功能亢进的疗效比较[J].医学信息,2019,32(05):154.[doi:10.3969/j.issn.1006-1959.2019.05.049]
 JIANG Hong-mei.Comparison of Propyl Thiouracil and Methimazole in the Treatment of Pregnancy with Hyperthyroidism[J].Medical Information,2019,32(10):154.[doi:10.3969/j.issn.1006-1959.2019.05.049]
[4]王 静,郭宏敏.肝型脂肪酸结合蛋白在糖尿病中的研究[J].医学信息,2019,32(18):18.[doi:10.3969/j.issn.1006-1959.2019.18.007]
 WANG Jing,GUO Hong-min.Study on Hepatic Fatty Acid Binding Protein in Diabetes[J].Medical Information,2019,32(10):18.[doi:10.3969/j.issn.1006-1959.2019.18.007]
[5]吕雅云,龚先琼.女贞子提取物治疗肝病的研究[J].医学信息,2020,33(03):31.[doi:10.3969/j.issn.1006-1959.2020.03.010]
 LYU Ya-yun,GONG Xian-qiong.Study on Ligustrum Lucidum Extract in Treating Liver Disease[J].Medical Information,2020,33(10):31.[doi:10.3969/j.issn.1006-1959.2020.03.010]
[6]郭 冶,卢凤美,刘东璞.肝纤维化发病机制及大黄酸对肝纤维化的作用[J].医学信息,2020,33(12):27.[doi:10.3969/j.issn.1006-1959.2020.12.010]
 GUO Ye,LU Feng-mei,LIU Dong-pu.The Pathogenesis of Hepatic Fibrosis and the Effect of Rhein on Hepatic Fibrosis[J].Medical Information,2020,33(10):27.[doi:10.3969/j.issn.1006-1959.2020.12.010]
[7]陈 玲,龚先琼.中药单体减轻对乙酰氨基酚诱导肝损伤的研究[J].医学信息,2021,34(15):1.[doi:10.3969/j.issn.1006-1959.2021.15.001]
 CHEN Ling,GONG Xian-qiong.Study on the Effect of Chinese Herbal Medicine on Reducing the Liver Injury Induced by Acetaminophen[J].Medical Information,2021,34(10):1.[doi:10.3969/j.issn.1006-1959.2021.15.001]
[8]张满英,吴春城,毛乾国,等.以肝功能损害为主要表现的EV71感染1例报道[J].医学信息,2021,34(19):187.[doi:10.3969/j.issn.1006-1959.2021.19.052]

更新日期/Last Update: 2020-05-15